Taro Announces New $250 Million Share Repurchase Authorization

HAWTHORNE, N.Y.--()--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that its Board of Directors has approved a new $250 million share repurchase authorization of its ordinary shares. This authorization follows the successful completion of the previous $250 million share repurchase program in August 2016.

Repurchases may be made from time to time at the Company’s discretion, based on ongoing assessments of the capital needs of the business, the market price of its stock, and general market conditions. No time period has been set for the repurchase program, and any such program may be suspended or discontinued at any time.

The repurchase authorization enables the Company to purchase its ordinary shares from time to time through open market purchases, negotiated transactions or other means, including 10b5-1 trading plans in accordance with applicable securities laws or other restrictions.

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.


Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although the Company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained, including without limitation statements in this press release regarding Taro's intention to repurchase its ordinary shares under the share repurchase programs. Factors that could cause actual results to differ include the market price of Taro’s stock, the nature of other investment opportunities presented to Taro, cash flows, general domestic and international economic conditions, industry and market conditions, changes in the Company's financial position, litigation brought by any party in any court in Israel, the United States, or any country in which Taro operates, regulatory and legislative actions in the countries in which Taro operates, and other risks detailed from time to time in the Company’s SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements are applicable only as of the date on which they are made. The Company undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.


Taro Pharmaceutical Industries Ltd.
Mariano Balaguer, (914) 345-9001
VP, Chief Financial Officer
William J. Coote, (914) 345-9001

Recent Stories

  • Taro Annual Report on Form 20-F Available
    June 22, 2018
    HAWTHORNE, N.Y.--(EON: Enhanced Online News)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2018, filed w... more »
  • Taro Provides Results for Year Ended March 31, 2018
    May 17, 2018
    HAWTHORNE, N.Y.--(EON: Enhanced Online News)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended Mar... more »
  • Taro to Announce Full Year Results on May 17, 2018
    May 11, 2018
    HAWTHORNE, N.Y.--(EON: Enhanced Online News)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2018, on Thursd... more »
RSS feed for Taro Pharmaceutical Industries Ltd.

Taro Pharmaceutical Industries Ltd.